DRL-Header DRL-Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

            Lead Product(s): Orvepitant Maleate

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: GW823296X

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Columbus Venture Partners

            Deal Size: $27.8 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing July 07, 2021

            Details:

            New funds to evaluate orvepitant as a treatment for the disabling chronic cough associated with idiopathic pulmonary fibrosis (IPF). The chronic cough can markedly reduce quality of life, is often refractory to medical therapy and there are no approved treatments for it.